CoolSculpting® Exhibiting At Summer AAD 2013

ZELTIQ ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it is exhibiting at the summer meeting of the American Academy of Dermatology (AAD) in New York, July 31-August 4, 2013. The company is showcasing CoolSculpting, its non-surgical, clinically proven procedure designed to selectively reduce fat in treated areas using a patented cooling technology.

For the complete summer AAD program, visit www.aad.org. For information about CoolSculpting, visit ZELTIQ at Booth #821.
         

WHAT:
CoolSculpting
ZELTIQ Booth #821
 

WHEN:
Summer AAD Exhibit Hours
Thursday, August 1, 2013, 10:00 a.m. – 6:00 p.m.
Friday, August 2, 2013, 10:00 a.m. – 6:00 p.m.
 

WHERE:
American Academy of Dermatology (AAD) Summer Meeting
Hilton New York Hotel
1335 Avenue of the Americas
New York, NY 10019
 

About ZELTIQ ® Aesthetics, Inc.

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably and measurably reduce the fat layer.

Copyright Business Wire 2010

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value